Skip to content

New Variants Involved in Taybi-Linder Syndrome

Identification of New Genes Involved in the Taybi-Linder Syndrome.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03222947
Acronym
NewViTALS
Enrollment
19
Registered
2017-07-19
Start date
2017-09-30
Completion date
2018-06-30
Last updated
2017-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Syndrome, Taybi Linder Syndrome

Brief summary

Taybi-Linder syndrome (TALS, OMIM 210710) is a rare autosomal recessive disorder belonging to the group of microcephalic osteodysplastic primordial dwarfisms (MOPD). This syndrome is characterized by short stature, skeletal anomalies, severe microcephaly with brain malformations and facial dysmorphism, and is caused by mutations in RNU4ATAC. Although RNU4ATAC-associated TALS is a recognizable phenotype, an atypical presentation is sometimes observed, thus expanding the clinical spectrum (TALS-like phenotype). This study aims to identify new variants involved in Taybi-Linder syndrome and associated phenotypes (i.e.TALS-like). This non interventional study will be performed on patients with no proven mutation of RNU4ATAC and their blood relatives (19 samples total) by high throughput sequencing and genetic analysis of already collected deoxyribonucleic acid samples. Altogether, such a study will allow a better understanding of the molecular mechanisms responsible for the Taybi-Linder syndrome and Taybi-Linder syndrome-like phenotypes as well as the pathophysiology of these devastating forms of microcephalic dwarfism.

Interventions

GENETICDeoxyribonucleic acid analysis

This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* foetus or young children diagnosed with a Taybi-Linder or Taybi-Linder like syndrome, with no RNU4ATAC mutation (index case) * aged 20 weeks pregnant to 18 years old * parents or sibling of the index cases, with informed consent for the analysis of both their DNA sample and the one of the index case.

Exclusion criteria

* no informed consent for the use of genetic samples for medical research

Design outcomes

Primary

MeasureTime frameDescription
Identification of new variants involved in the Taybi-Linder syndromeCollection at time of diagnosis = less than one dayA genetic high throughput exome capture sequencing of 19 deoxyribonucleic acid samples from patients diagnosed with a Taybi-Linder like syndrome and their blood relatives

Countries

France

Contacts

Primary ContactAudrey PUTOUX, MCU-PH
audrey.putoux@chu-lyon.fr04 27 85 50 83
Backup ContactCharles EDERY, PU-PH
charles.edery@chu-lyon.fr04 27 85 55 73

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026